Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
---|---|---|---|---|---|
M5.001.001 | Viscosupplementation Therapy For Knee | May 14, 2025 | May 20, 2026 | Viscosupplementation therapy is part of the therapy used in the treatment of osteoarthritis of the knee.... | Ver |
M5.001.002 | Rituximab | May 14, 2025 | May 20, 2026 | Rituximab is a genetically engineered chimeric murine/human monoclonal igg1 kappa antibody directed against... | Ver |
M5.001.003 | Trastuzumab – Trastuzumab Biologics | May 14, 2025 | May 20, 2026 | Trastuzumab is a monoclonal antibody, one of a group of drugs designed to attack specific cancer cells.... | Ver |
M5.001.005 | Bevacizumab | May 14, 2025 | May 20, 2026 | Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor a... | Ver |
M5.001.006 | G-Csf Filgrastim | May 14, 2025 | May 20, 2026 | White blood cell growth factors, also known as granulocyte colony stimulating factors (g-csf), are... | Ver |
M5.001.007 | Somatuline® Depot; Lanreotide | May 14, 2025 | May 20, 2026 | Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... | Ver |
M5.001.008 | Simponi ARIA® (golimumab) | May 14, 2025 | May 20, 2026 | Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... | Ver |
M5.001.009 | Stelara® (ustekinumab) | May 14, 2025 | May 20, 2026 | Stelara is a human igg1κ monoclonal antibody that binds with high affinity and specificity to the p40... | Ver |
M5.001.010 | Infliximab | May 14, 2025 | May 20, 2026 | Infliximab (remicade®) is a tumor necrosis factor α (tnf-α) blocking agent approved by the... | Ver |
M5.001.011 | Erythropoiesis Stimulating Agents | May 14, 2025 | May 20, 2026 | Endogenous erythropoietin is a glycoprotein hematopoietic growth factor that regulates hemoglobin levels in... | Ver |
M5.001.012 | Vascular Endothelial Growth Factor Inhibitors for the Treatment of Ophthalmological Diseases | May 14, 2025 | May 20, 2026 | Vascular endothelial growth factor has been implicated in the pathogenesis of a variety of ocular vascular... | Ver |
M5.001.013 | Ruconest | May 14, 2025 | May 20, 2026 | C-1 esterase inhibitor protein is one of nine complement proteins found in the blood that works with the... | Ver |
M5.001.014 | Immune Globulin | May 14, 2025 | May 20, 2026 | Immune globulin (also referred to as gamma globulin or immunoglobulin) is a therapeutic compound prepared... | Ver |
M5.001.015 | Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adult Patients | May 14, 2025 | May 20, 2026 | Hereditary transthyretin-mediated amyloidosis (hattr) is a rare, progressive, and fatal autosomal dominant... | Ver |
M5.001.016 | Lumasiran for Primary Hyperoxaluria Type 1 | May 14, 2025 | May 20, 2026 | Primary hyperoxalurias are a group of rare genetic diseases. there are 3 subtypes each resulting in the... | Ver |
M5.001.017 | Hemophilia Antihemophilic Factor | May 14, 2025 | May 20, 2026 | The hemophilias are a group of related bleeding disorders that most commonly are inherited. inherited... | Ver |
M5.001.018 | Nucala® (mepolizumab) | May 14, 2025 | May 20, 2026 | Mepolizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
M5.001.019 | Fasenra® (benralizumab) | May 14, 2025 | May 20, 2026 | Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... | Ver |
M5.001.020 | Givosiran for Acute Hepatic Porphyria | May 14, 2025 | May 20, 2026 | Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... | Ver |
M5.001.021 | Biological Treatments for Refractory Myasthenia Gravis | May 14, 2025 | May 20, 2026 | Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... | Ver |